Home
/

What is an LDL/HDL Ratio Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The LDL/HDL ratio compares cholesterol in delivery-oriented LDL particles to protective HDL particles, revealing the net direction of cholesterol traffic between artery walls and the liver. Most people fall around 2–3; lower values (toward 1 or below) reflect efficient reverse cholesterol transport, while higher ratios are associated with plaque formation and vascular dysfunction. This single index may help support atherosclerotic risk assessment better than total cholesterol alone.

Read more →
Table of contents

The LDL/HDL Ratio as a Single Index of Cholesterol Traffic

LDL/HDL ratio blood testing reports the balance between two major cholesterol carriers in your bloodstream. LDL (low-density lipoprotein) mainly delivers cholesterol from the liver to body tissues. It is formed as VLDL from the liver sheds triglycerides and becomes cholesterol-rich LDL. HDL (high-density lipoprotein) is produced by the liver and intestine as small, protein-dense particles that pick up excess cholesterol from tissues and the bloodstream. The ratio is simply LDL cholesterol divided by HDL cholesterol—a calculated index, not a standalone molecule.

This ratio reflects the direction of cholesterol traffic in the body: delivery into tissues, including artery walls, versus return to the liver for reuse or disposal (reverse cholesterol transport). LDL represents outward transport; HDL represents cleanup and return. By comparing them, the ratio summarizes the prevailing influence of cholesterol-delivering, atherogenic particles (apoB-containing LDL) relative to cholesterol-scavenging, anti-atherogenic particles (apoA-I–containing HDL). In essence, it captures the net balance of lipoprotein activity that shapes how cholesterol is handled within arteries (atherogenesis) and throughout the body's lipid economy.

How the Ratio Forecasts Arterial and Vascular Risk

The LDL/HDL ratio captures the balance between cholesterol delivery to tissues (LDL) and cholesterol retrieval back to the liver (HDL). It summarizes how your body moves fats through the bloodstream, forecasting arterial health, endothelial function, and inflammation—and therefore your long-term risk for heart attack, stroke, and peripheral artery disease.

It reflects the balance between atherogenic particles and reverse cholesterol transport, integrating liver function, endocrine signals, insulin sensitivity, and inflammation. A lower ratio generally means less arterial lipid burden and better endothelial health, with implications for heart, metabolic, and brain vascular function.

Where Most People Land — And What Higher or Lower Numbers Signal

Most people fall somewhere around 2–3; lower values are generally more favorable, with values near 1 or below reflecting a protective profile. A low ratio usually means low LDL and/or high HDL, pointing to efficient reverse cholesterol transport and a lighter atherogenic load. People feel well and often have no symptoms. In rare inherited conditions with very low LDL, there can be fat-soluble vitamin deficiency, neurologic issues, or liver fat accumulation, but this is uncommon.

Low values usually reflect lower LDL relative to HDL, indicating active cholesterol clearance and fewer apoB-containing particles. This is common in youth and premenopausal women due to estrogen effects, and in some genetic patterns. Very low ratios can stem from very low LDL; rarely, this coincides with reduced transport of fat-soluble vitamins or steroid precursors.

Being in range suggests a stable balance of lipid delivery and removal, efficient hepatic processing, and quieter vascular inflammation. For most groups, cardiovascular risk tends to be lowest toward the lower end of the lab range, assuming HDL is functional and triglycerides are not markedly elevated.

A higher ratio means LDL outweighs HDL, tilting physiology toward plaque formation, impaired nitric oxide signaling, and vascular stiffness. This can remain silent for years, then show up as exertional chest pressure, calf pain with walking, transient neurologic symptoms, or erectile dysfunction. Men typically have higher ratios than premenopausal women; ratios rise after menopause. Pregnancy naturally raises LDL and can raise the ratio. In children and teens, a high ratio may signal familial hypercholesterolemia and early arterial changes.

This pattern is common with insulin resistance, low thyroid hormone, menopause, nephrotic syndrome, and some genetic dyslipidemias. Higher ratios associate with atherosclerotic cardiovascular disease risk, fatty liver, and microvascular dysfunction affecting kidneys, retina, and cognition.

What Can Distort the Calculated Ratio

Nonfasting status, acute illness, and inflammation often lower HDL and raise the ratio. Pregnancy increases cholesterol and can shift the ratio. Calculated LDL depends on triglycerides; very high triglycerides make the ratio less reliable. ApoB or non-HDL cholesterol can add context.

Big picture: this ratio integrates lipid transport with metabolism, inflammation, and hormonal states. It complements non-HDL cholesterol, apolipoprotein B, triglycerides, glucose control, thyroid and kidney function, and better predicts atherosclerotic risk than total cholesterol alone over time.

FAQs

The LDL/HDL Ratio is the amount of LDL cholesterol relative to HDL cholesterol. Lower ratios generally indicate lower cardiovascular risk.

A higher ratio suggests LDL burden outweighs HDL protection and is associated with greater risk.

It is calculated by dividing LDL cholesterol by HDL cholesterol, both taken from a standard lipid panel.

Fasting is often recommended for lipid panels but is not always required unless specified.

Frequency depends on your risk profile and goals. Many people retest periodically to monitor lifestyle changes and long-term trends.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
  2. Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, L. F., Masana, L., Mangas, A., Hernández-Mijares, A., González-Santos, P., Ascaso, J. F., & Pedro-Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management, 5, 757-765. https://doi.org/10.2147/VHRM.S6269
  3. Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
  4. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  5. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey